A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human])
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objectives of the study are:
- To assess the safety and tolerability of escalating doses of CINRYZE.
- To assess the effect of an escalating dose algorithm for CINRYZE on HAE attack rates.
- To assess the immunogenicity of CINRYZE.
| Condition | Intervention | Phase |
|---|---|---|
|
Hereditary Angioedema C1 Esterase Inhibitor Deficiency |
Biological: C1 inhibitor (human) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks. |
- Safety will be assessed by recording the incident and severity of adverse events as well as by monitoring vital signs, clinical laboratory tests, C1INH antibody levels, and the frequency and related details of episodes of thrombosis.
- Efficacy assessments will include incidents of any HAE attacks as determined by patient reported diary data, use of rescue therapy, hospitalization and/or use of other therapy for treating a HAE attack.
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2009 |
| Estimated Study Completion Date: | October 2012 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
-
Biological: C1 inhibitor (human)
This open-label, multicenter, Phase 4 study will assess escalating doses of CINRYZE as prophylactic therapy to lower the HAE attack rate in subjects who are not adequately controlled at the recommended CINRYZE dosing regimen.
There will be three potential dose escalation steps for 12 week periods each:
Step 1: 1500 Units twice per week Step 2: 2000 Units twice per week Step 3: 2500 Units twice per week
Eligibility| Ages Eligible for Study: | 6 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
To be eligible for this protocol, subjects must:
- Be ≥6 years of age and ≥25 kg body weight
Have a confirmed diagnosis of HAE with a documented history of swelling of the face, extremities, gastrointestinal tract, genitalia, or larynx and a history of at least one of the following:
- C1 inhibitor (C1 INH) gene mutation
- C4 level below the lower limit of the reference range
- C1 inhibitor antigen level below the lower limit of the reference range
- Functional C1 inhibitor level below the lower limit of the reference range
- Family history of HAE (i.e., grandparent, parent, sibling)
- Have a history of >1.0 HAE attack per month (average) of any severity over the 3 consecutive months prior to screening while receiving the recommended Cinryze dosing of 1000 U every 3 to 4 days via intravenous injection.
- If an adult, be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.
OR If a child, have a parent/legal guardian who is willing and able to provide written informed consent for the child to participate in the study (with assent from the child when appropriate).
Exclusion Criteria:
To be eligible for this protocol, subjects must not:
- Have, as determined by the investigator and/or the sponsor's medical monitor, any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results.
- Have a history of abnormal blood clotting or other coagulopathy.
- Be taking prescription anticoagulation medication
- Have a history of allergic reaction to Cinryze or other blood products.
- Have participated in any other investigational drug study within the past 30 days (other than Cinryze protocols).
- Have received any blood products (other than Cinryze) within 60days prior to screening.
Have any of the following laboratory values at screening:
- Hemoglobin <8 g/dL
- White blood cell (WBC) count <2 x 109/L or >20 x 109/L
- Platelet count <50 x 109/L or >400 x 109/L
- Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.0 x the upper limit of normal
- Blood urea nitrogen (BUN) and/or creatinine >2.0 x the upper limit of normal
- Be pregnant or breastfeeding
Contacts and Locations| United States, Arizona | |
| Allergy and Immunology Associates | |
| Scottsdale, Arizona, United States, 85251 | |
| United States, California | |
| UCLA Medical Center | |
| Los Angeles, California, United States, 90095 | |
| Donald S. Levy, M.D. | |
| Orange, California, United States, 92868 | |
| United States, Georgia | |
| Family Allergy and Asthma Center | |
| Atlanta, Georgia, United States, 30342 | |
| United States, Maryland | |
| Institute for Asthma and Allergy | |
| Wheaton, Maryland, United States, 20902 | |
| United States, New York | |
| Winthrop University Hospital | |
| Mineola, New York, United States, 11501 | |
| United States, Ohio | |
| University of Cincinnati Medical Center | |
| Cincinnati, Ohio, United States, 45267 | |
| United States, Oregon | |
| Baker Allergy, Asthma and Dermatology Research Center | |
| Lake Oswego, Oregon, United States, 97035 | |
| United States, Tennessee | |
| East Tennessee Center for Clinical Research | |
| Knoxville, Tennessee, United States, 37909 | |
| United States, Texas | |
| Mark J. Florian, MD, PA | |
| Bryan, Texas, United States, 77802 | |
| AARA Research Center | |
| Dallas, Texas, United States, 75231 | |
| Allergy and Asthma Research Center | |
| San Antonio, Texas, United States, 78229 | |
| United States, Washington | |
| Marycliff Allergy Specialist | |
| Spokane, Washington, United States, 99204 | |
| Puget Sound Allergy, Asthma & Immunology | |
| Tacoma, Washington, United States, 98405 | |
More Information
No publications provided
| Responsible Party: | Marc E. Uknis, MD FACS, ViroPharma Incorporated |
| ClinicalTrials.gov Identifier: | NCT00914966 History of Changes |
| Other Study ID Numbers: | 0624-400 |
| Study First Received: | June 3, 2009 |
| Last Updated: | May 9, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by ViroPharma:
|
HAE C1 inhibitor C1INH |
Additional relevant MeSH terms:
|
Angioedema Angioedemas, Hereditary Vascular Diseases Cardiovascular Diseases Urticaria Skin Diseases, Vascular Skin Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |
Genetic Diseases, Inborn Complement C1 Inhibitor Protein Complement C1 Inactivator Proteins Complement C1 Complement Inactivating Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 16, 2013